Axonics (Axonics) Operating Cash Flow per Share

: $-0.04 (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

Axonics's operating cash flow per share for the three months ended in Dec. 2023 was $0.11. Axonics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.04.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Axonics was -160.30% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 73.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Axonics's Operating Cash Flow per Share or its related term are showing as below:

AXNX' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -45.8 Med: 2.5 Max: 73.7
Current: 73.7

During the past 8 years, Axonics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 73.70% per year. The lowest was -45.80% per year. And the median was 2.50% per year.

AXNX's 3-Year OCF Growth Rate is ranked better than
95.76% of 684 companies
in the Medical Devices & Instruments industry
Industry Median: 4.7 vs AXNX: 73.70

Axonics Operating Cash Flow per Share Historical Data

The historical data trend for Axonics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axonics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

-2.92

-2.26

-1.10

0.07

-0.04

Axonics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share																0.19	-0.02	-0.39	0.25	0.11

Competitive Comparison

For the Medical Devices subindustry, Axonics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Axonics Price-to-Operating-Cash-Flow Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Axonics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Axonics's Price-to-Operating-Cash-Flow falls into.

Axonics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Axonics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-2.016	/	49.081
	=	-0.04

Axonics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	5.63	/	49.406
	=	0.11

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04

Axonics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Axonics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Axonics (Axonics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (NAS:AXNX) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

0I3:Germany 0I3:Germany

Address

26 Technology Drive, Irvine, CA, USA, 92618

Website

https://www.axonics.com

Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.

Executives

Karen Noblett	officer: Chief Medical Officer	26 TECHNOLOGY DRIVE, IRVINE CA 92618
Kari Leigh Keese	officer: Chief Financial Officer	15205 LAFAYETTE WAY, TUSTIN CA 92782
Danny L. Dearen	officer: See Remarks	26 TECHNOLOGY DRIVE, IRVINE CA 92618
Ford Alfred J Jr	officer: Chief Commercial Officer	3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Rinda Sama	officer: Chief Operating Officer	26 TECHNOLOGY DRIVE, IRVINE CA 92618
John Woock	officer: Chief Marketing Officer	26 TECHNOLOGY DRIVE, IRVINE CA 92618
Raymond W Cohen	director, officer: Chief Executive Officer
Esteban Lopez	director	6303 COWBOYS WAY, SUITE 600, FRISCO TX 75034
Jane E Kiernan	director	525 W ROSCOE, CHICAGO IL 60657
Robert Mcnamara	director	C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
David M Demski	director	C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Robert E Mcnamara	director	C/O NORTHSTAR NEUROSCIENCE, INC., 2401 FOURTH AVENUE, SUITE 300, SEATTLE WA 98121
Bakker Juliet Tammenoms	director, 10 percent owner	LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Partners Andera	10 percent owner	374 RUE SAINT ST HONORE, PARIS I0 75001
Raphael Wisniewski	director, 10 percent owner	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920